X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Develco Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 24, 2021
Details:
HMNC and Develco Pharma have created a joint venture and formed the company Ketabon, which will initiate a Contract Research Organization led proof-of-concept study of an investigational oral prolonged-release formulation of ketamine targeting treatment-resistant depression.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI 425809
Therapeutic Area: Psychiatry/Psychology Product Name: BI 425809
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2021
Details:
CONNEX is a Phase III clinical trial program designed to assess the safety and efficacy of BI 425809 for improving cognition in adult
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
